{"title_page": "Kelatorphan", "text_new": "{{Drugbox\n| IUPAC_name               = ''N''-[(2''R'')-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]-<small>L</small>-[[alanine]]\n| image                    = Kelatorphan.svg\n| CAS_number               = 92175-57-0\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 46BBW2U5D6\n| ATC_prefix               = None\n| ATC_suffix               = \n| PubChem                  = 123982\n| DrugBank                 = DB08040\n| ChemSpiderID             = 110501\n| C = 14 | H = 18 | N = 2 | O = 5\n| molecular_weight         = 294.303 g/mol\n| smiles                   = O=C(O)[C@@H](NC(=O)[C@H](Cc1ccccc1)CC(=O)NO)C\n| StdInChI                 = 1S/C14H18N2O5/c1-9(14(19)20)15-13(18)11(8-12(17)16-21)7-10-5-3-2-4-6-10/h2-6,9,11,21H,7-8H2,1H3,(H,15,18)(H,16,17)(H,19,20)/t9-,11+/m0/s1\n| StdInChIKey              = OJCFZTVYDSKXNM-GXSJLCMTSA-N\n| bioavailability          = \n| protein_bound            = \n| metabolism               = \n| elimination_half-life    = \n| excretion                = \n| pregnancy_category       = \n| legal_status             = Non-regulated\n| routes_of_administration = \n}}\n\n'''Kelatorphan''' is a [[drug]] which acts as a powerful and complete [[enzyme inhibitor|inhibitor]] of nearly all of the [[enzyme]]s responsible for [[catabolism]] of the [[endogenous]] [[enkephalin]]s, including [[neutral endopeptidase]] (NEP), [[dipeptidyl peptidase III]] (DPP3), [[aminopeptidase N]] (APN), and [[angiotensin-converting enzyme]] (ACE).<ref name=\"pmid6386492\">{{cite journal  |vauthors=Fournie-Zaluski MC, Chaillet P, Bouboutou R, etal | title = Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes | journal = European Journal of Pharmacology | volume = 102 | issue = 3\u20134 | pages = 525\u20138 |date=July 1984 | pmid = 6386492 | doi = 10.1016/0014-2999(84)90575-2| url = }}</ref><ref name=\"pmid12470213\">{{cite journal|vauthors=Yamamoto Y, Ono H, Ueda A, Shimamura M, Nishimura K, Hazato T |title=Spinorphin as an endogenous inhibitor of enkephalin-degrading enzymes: roles in pain and inflammation |journal=Current Protein & Peptide Science |volume=3 |issue=6 |pages=587\u201399 |date=December 2002 |pmid=12470213 |doi=10.2174/1389203023380404 |url=http://www.benthamdirect.org/pages/content.php?CPPS/2002/00000003/00000006/0002K.SGM |archive-url=https://archive.is/20130414102134/http://www.benthamdirect.org/pages/content.php?CPPS/2002/00000003/00000006/0002K.SGM |url-status=dead |archive-date=2013-04-14 }}</ref><ref name=\"ZwietenGreenlee1997\">{{cite book | author1 = P. A. van Zwieten | author2 = William J. Greenlee | title = Antihypertensive Drugs | url = https://books.google.com/books?id=f8OO3B7eD6wC&pg=PA192 | accessdate = 25 November 2011 | date = 5 September 1997 | publisher = CRC Press | isbn = 978-90-5702-122-0 | page = 192}}</ref> In mice, with the intracerebroventricular co-administration of a 50&nbsp;\u00b5g dose of kelatorphan (this route is necessary because kelatorphan is incapable of crossing the [[blood-brain-barrier]])<ref name=\"pmid11166965\">{{cite journal |vauthors=Boudinot E, Morin-Surun M, Foutz AS, Fourni\u00e9-Zaluski M, Roques BP, Denavit-Saubi\u00e9 M | title = Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration | journal = Pain | volume = 90 | issue = 1\u20132 | pages = 7\u201313 |date=February 2001 | pmid = 11166965 | doi = 10.1016/S0304-3959(00)00382-1}}</ref> hence alongside [[exogenous]] [[Met-enkephalin|[Met]enkephalin]] ([[ED50|ED<sub>50</sub>]] approximately 10&nbsp;ng), it potentiated the [[analgesic]] effects of the latter by 50,000 times.<ref name=\"pmid6386492\" /> Kelatorphan also displays [[potency (pharmacology)|potent]] [[antinociceptive]] effects alone,<ref name=\"pmid2790459\">{{cite journal |vauthors=Kayser V, Fournie-Zaluski MC, Guilbaud G, Roques BP | title = Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin-degrading enzymes) systemically administered in normal and arthritic rats | journal = Brain Research | volume = 497 | issue = 1 | pages = 94\u2013101 |date=September 1989 | pmid = 2790459 | doi = 10.1016/0006-8993(89)90974-8}}</ref> and does not depress [[Cellular respiration|respiration]], although at high doses it actually increases it.<ref name=\"pmid11166965\"/>\n\n== See also ==\n* [[Enkephalinase inhibitor]]\n\n== References ==\n{{Reflist|2}}\n\n{{Opioidergics}}\n\n[[Category:Amino acids]]\n[[Category:Analgesics]]\n[[Category:Enkephalinase inhibitors]]\n[[Category:Opioids]]\n[[Category:Peripherally selective drugs]]\n", "text_old": "{{Drugbox\n| IUPAC_name               = ''N''-[(2''R'')-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]-<small>L</small>-[[alanine]]\n| image                    = Kelatorphan.svg\n| CAS_number               = 92175-57-0\n| ATC_prefix               = None\n| ATC_suffix               = \n| PubChem                  = 123982\n| DrugBank                 = DB08040\n| ChemSpiderID             = 110501\n| C = 14 | H = 18 | N = 2 | O = 5\n| molecular_weight         = 294.303 g/mol\n| smiles                   = O=C(O)[C@@H](NC(=O)[C@H](Cc1ccccc1)CC(=O)NO)C\n| StdInChI                 = 1S/C14H18N2O5/c1-9(14(19)20)15-13(18)11(8-12(17)16-21)7-10-5-3-2-4-6-10/h2-6,9,11,21H,7-8H2,1H3,(H,15,18)(H,16,17)(H,19,20)/t9-,11+/m0/s1\n| StdInChIKey              = OJCFZTVYDSKXNM-GXSJLCMTSA-N\n| bioavailability          = \n| protein_bound            = \n| metabolism               = \n| elimination_half-life    = \n| excretion                = \n| pregnancy_category       = \n| legal_status             = Non-regulated\n| routes_of_administration = \n}}\n\n'''Kelatorphan''' is a [[drug]] which acts as a powerful and complete [[enzyme inhibitor|inhibitor]] of nearly all of the [[enzyme]]s responsible for [[catabolism]] of the [[endogenous]] [[enkephalin]]s, including [[neutral endopeptidase]] (NEP), [[dipeptidyl peptidase III]] (DPP3), [[aminopeptidase N]] (APN), and [[angiotensin-converting enzyme]] (ACE).<ref name=\"pmid6386492\">{{cite journal  |vauthors=Fournie-Zaluski MC, Chaillet P, Bouboutou R, etal | title = Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes | journal = European Journal of Pharmacology | volume = 102 | issue = 3\u20134 | pages = 525\u20138 |date=July 1984 | pmid = 6386492 | doi = 10.1016/0014-2999(84)90575-2| url = }}</ref><ref name=\"pmid12470213\">{{cite journal|vauthors=Yamamoto Y, Ono H, Ueda A, Shimamura M, Nishimura K, Hazato T |title=Spinorphin as an endogenous inhibitor of enkephalin-degrading enzymes: roles in pain and inflammation |journal=Current Protein & Peptide Science |volume=3 |issue=6 |pages=587\u201399 |date=December 2002 |pmid=12470213 |doi=10.2174/1389203023380404 |url=http://www.benthamdirect.org/pages/content.php?CPPS/2002/00000003/00000006/0002K.SGM |archive-url=https://archive.is/20130414102134/http://www.benthamdirect.org/pages/content.php?CPPS/2002/00000003/00000006/0002K.SGM |url-status=dead |archive-date=2013-04-14 }}</ref><ref name=\"ZwietenGreenlee1997\">{{cite book | author1 = P. A. van Zwieten | author2 = William J. Greenlee | title = Antihypertensive Drugs | url = https://books.google.com/books?id=f8OO3B7eD6wC&pg=PA192 | accessdate = 25 November 2011 | date = 5 September 1997 | publisher = CRC Press | isbn = 978-90-5702-122-0 | page = 192}}</ref> In mice, with the intracerebroventricular co-administration of a 50&nbsp;\u00b5g dose of kelatorphan (this route is necessary because kelatorphan is incapable of crossing the [[blood-brain-barrier]])<ref name=\"pmid11166965\">{{cite journal |vauthors=Boudinot E, Morin-Surun M, Foutz AS, Fourni\u00e9-Zaluski M, Roques BP, Denavit-Saubi\u00e9 M | title = Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration | journal = Pain | volume = 90 | issue = 1\u20132 | pages = 7\u201313 |date=February 2001 | pmid = 11166965 | doi = 10.1016/S0304-3959(00)00382-1}}</ref> hence alongside [[exogenous]] [[Met-enkephalin|[Met]enkephalin]] ([[ED50|ED<sub>50</sub>]] approximately 10&nbsp;ng), it potentiated the [[analgesic]] effects of the latter by 50,000 times.<ref name=\"pmid6386492\" /> Kelatorphan also displays [[potency (pharmacology)|potent]] [[antinociceptive]] effects alone,<ref name=\"pmid2790459\">{{cite journal |vauthors=Kayser V, Fournie-Zaluski MC, Guilbaud G, Roques BP | title = Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin-degrading enzymes) systemically administered in normal and arthritic rats | journal = Brain Research | volume = 497 | issue = 1 | pages = 94\u2013101 |date=September 1989 | pmid = 2790459 | doi = 10.1016/0006-8993(89)90974-8}}</ref> and does not depress [[Cellular respiration|respiration]], although at high doses it actually increases it.<ref name=\"pmid11166965\"/>\n\n== See also ==\n* [[Enkephalinase inhibitor]]\n\n== References ==\n{{Reflist|2}}\n\n{{Opioidergics}}\n\n[[Category:Amino acids]]\n[[Category:Analgesics]]\n[[Category:Enkephalinase inhibitors]]\n[[Category:Opioids]]\n[[Category:Peripherally selective drugs]]\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Kelatorphan"}
